Real-life efficiency and safety comparison study of emollient ointment based on glycerophosphoinositol (GPI) salt of choline and other emollient products in patients with atopic dermatitis

Abstract

Introduction The aim of this study was to investigate the effectiveness and safety of emollient preparations in comparison with the emollient ointment containing glycerophosphoinositol salt of choline in patients with atopic dermatitis (AD). Methods In a ‘real–life’ study, 300 patients with moderate AD were age-stratified and divided into two groups: patients applying GPI emollient and the comparator. We evaluated the effectiveness of AD treatment using: Eczema Area and Severity Index (EASI), Three Item Severity (TIS), Visual Analogue Scale (VAS) and Four-Item Itch Questionnaire. Results The GPI emollient was superior in reduction AD symptoms in children: VAS (−2.58 ± 0.25), TIS (−2.22 ± 0.22), EASI (−15.27 ± 1.77), and adults: VAS (−2.42 ± 0.19), TIS (−2.22 ± 0.17), EASI (−13.22 ± 1.53), as compared to the other emollient in children: VAS (−0.67 ± 0.19), TIS (0.47 ± 0.19), EASI (−3.71 ± 1.01) and adults: VAS (−0.86 ± 0.09), TIS (0.77 ± 0.09), EASI (−2.95 ± 0.46), p < .001. Similar results were observed in Four Item Itch Questionnaire. Conclusion Both emollients showed good safety and tolerance profile and reduced AD symptoms. The GPI emollient seems to be more slightly effective in reducing AD symptoms as compared to the other commercially available emollient.